Christopher Turner

Christopher Turner

Plus aucun poste en cours
58 ans
Health Technology
Health Services
Consumer Services

Profil

Christopher D.
Turner
worked as Head-Clinical Research at ARIAD Pharmaceuticals, Inc. from 2008 to 2014.
From 2014 to 2018, served as Vice President-Clinical Science at Celldex Therapeutics, Inc. Between 2018 and 2021, held the position of Vice President-Clinical Development at Blueprint Medicines Corp.
Formerly held roles as Director-Pediatric Neuro Oncology Outcomes at Dana-Farber Cancer Institute, Inc. and Director-Pediatric Neuro Oncology Outcomes Clinic at The Children's Hospital Corp.
From 2021 to 2026, worked as Chief Medical Officer at Nuvalent, Inc. Education includes undergraduate studies at Bowdoin College and a doctorate from the University of Rochester School of Medicine & Dentistry.

Anciens postes connus de Christopher Turner

SociétésPosteFin
NUVALENT, INC. Directeur Technique/Scientifique/R&D 15/07/2026
BLUEPRINT MEDICINES CORPORATION Corporate Officer/Principal 01/03/2021
CELLDEX THERAPEUTICS, INC. Corporate Officer/Principal 01/05/2018
ARIAD PHARMACEUTICALS, INC. Directeur Technique/Scientifique/R&D 01/07/2014
Corporate Officer/Principal -
Voir l'expérience en détail de Christopher Turner

Formation de Christopher Turner

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

64

Relations au 1er degré

8

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées8

Health Technology

Health Services

Consumer Services

Health Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Bourse
  2. Insiders
  3. Christopher Turner
🔇